

IMI2 - Calls 15-16: Opportunities for SMEs

Jul 23, 2018

First Name	Last Name	Email	Country	Organisation	Which IMI2 - Call 15 & 16 topic(s) are you most interested in?	Briefly, what would you bring to the project in terms of expertise, resources, activities?
Joseph	Andre	joseph.andre@pulsalys.fr	France	PULSALYS		
Antonio	Artés	antonio@eb2.tech	Spain	Evidence-Based Behavior		
Jucov	Artiom	artiom.jucov@h2020.md	Moldova, Republic of	National Agency for Research and Development		
Farah Gonul	Aydin	farahgonul.aydin@gmail.com	Turkey	Ankara Uni.Faculty of Veterinary Medicine	Blockchain in heath, pharmacology	
Helena	Azevedo	h.azevedo@qmul.ac.uk	United Kingdom	Queen Mary University of London	5 and 7	peptide nanotechnology
Edita	Bagdonaite	edita.bagdonaite@mita.lt	Lithuania	Agency for Science, Innovation and Technology		
Charli	Batley	charli.batley@phoremot.com	United Kingdom	Phoremot Ltd	Synaptopathy	Drug Discovery Platform
Florian	Berner	florian.berner@euresearch.ch	Switzerland	ZHAW Zürcher Hochschule für Angewandte Wissenschaften, Ressort Forschung & Entwicklung		
Carlos	Boto	csmboto@dodoc.com	Portugal	doDOC - Accelerating the creation of medical products by streamlining R&D, medical communications and regulatory documentation	R&D & regulatory processes	doDOC allows several people to work on the same document at the same time obtaining a full audit-trail of any document.
Justine	Bounet	jbounet@cci-paris-idf.fr	France	ENTERPRISE EUROPE NETWORK		
Ena	Brophy	ena.brophy@nuigalway.ie	Ireland	BioInnovate Ireland NUI Galway	SME involvement	
Florian	Burg	florian.burg@healthcarefuturists.com	Germany	HealthCare Futurists GmbH		
Daniela	Buser	daniela.buser@fhnw.ch	Switzerland	FHNW	Blockchain enabled healthcare, Digital Transformation	
Jonathan	Butcher	jonathan.j.butcher@bioversys.com	Switzerland	BioVersys	Topic 6	Expertise in AMR, especially TB, a well-established TB network, drug R&D capabilities, know-how and own preclinical programs

IMI2 - Calls 15-16: Opportunities for SMEs

Jul 23, 2018



First Name	Last Name	Email	Country	Organisation	Which IMI2 - Call 15 & 16 topic(s) are you most interested in?	Briefly, what would you bring to the project in terms of expertise, resources, activities?
Célia	Cabral	celia.cabral@fmed.uc.pt	Portugal	Faculdade de Medicina, Universidade de Coimbra		
Laura	Castaneda	laura@plasmiabiotech.com	Spain	Plasmia Biotech SL	Call 16	Libraries of molecules, expertise in medical chemistry and Drug discovery
Janete	Chung	janete.chung@uis.no	Norway	Stavanger Hospital University		
Ana Maria	Cintora	anamariacintora@gmail.com	Spain	Medical Urgency Services Madrid SUMMA 112	Both	Experience and opportunities about contact with patients in medium and big urgencies
Rene	Coppens	rene.coppens@tbvi.eu	Netherlands	TuBerculosis Vaccine Initiative	TB drug translational development	Scientific coordination / Project management
Isabel	Cruz	isabel.cruz@hltsys.pt	Portugal	HLTSYS-HealthySystems, Lda.	Call 15- Topic 1 and Topic 2	
Susanne	Daniel	susanne.daniel@unibas.ch	Switzerland	Euresearch, University of Basel	all	support and bring Swiss partners in proposals
Aniek	Doensen	aniek.doensen@catalyze.nl	Netherlands	Catalyze		
Christian	Dr. Fritsch	cfritsch@ascrion.com	Germany	ascrion	Call 15: „AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries“	We offer a communication tool for research consortia and platforms for webinars, videoconferences, online-partnering
Rafael	Espinosa	rafaelespinosa@rti.eu	Spain	RTDI	Blockchain	
Sofia	Fernandes	sofia.fernandes@ucp.pt	Portugal	CREATING HEALTH		
Astrid	Flandorfer	astrid.flandorfer@ffg.at	Austria	FFG		
Tim	Fugmann	tim.fugmann@philochem.ch	Switzerland	Philochem AG	Microenvironment imposed signatures in tissue and liquid biopsies in immune mediated disease	Our sHLA peptidomics platform, a novel liquid biopsy method to detect signatures for immune mediated diseases
Matteo	Gabetta	matteo.gabetta@biomeris.com	Italy	BIOMERIS	Call 15: TOPIC 1 and TOPIC2	Technology for querying EHRs, registries, data warehouses and Real World Data. Data integration and data harmonization.
Maria Julia	Gomes De Moura	mariajuliamoura@ics.lisboa.ucp.pt	Portugal	UCP		
Liat	Haklai Topper	liat.topper@virucure.com	Israel	Virucure therapeutics	Integrated research platforms enabling patientcentric drug development	a start up dedicated to R&D on a proprietary oncolytic viral platform intended to treat GBM and other tumors

IMI2 - Calls 15-16: Opportunities for SMEs

Jul 23, 2018



First Name	Last Name	Email	Country	Organisation	Which IMI2 - Call 15 & 16 topic(s) are you most interested in?	Briefly, what would you bring to the project in terms of expertise, resources, activities?
Panagiotis	Ignatiadis	ignatiadis@help-forward.gr	Greece	praxi network		
Laura	Isús	laura.isus@genomcore.com	Spain	Genomcore	Blockchain enabled healthcare	
Maria Dolores	Julian	drmdjulian@hotmail.com	Spain	Freelance		
Wim	Korevaar	wim@dot.world	Netherlands	DOT.world		We develop expert platforms for knowledge networks & research consortia, with a strong focus on collaboration and dissemination.
Christina	Lercher	christina.lercher@standort-tirol.at	Austria	Standortagentur Tirol		
Iraida	Loinaz	iloinaz@cidetec.es	Spain	Fundación CIDETEC	Call 16, Topic 5	New platform for drug delivery, GMP Manufacturing.
Peadar	Macgabhann	peadar@biostor.eu	Ireland	Biostór Ireland	Microenvironment imposed signatures in tissue and liquid biopsies in immune mediated disease	A biobank of 50,000 samples collected to investigate immune, proteomic and genomic signatures in corneal transplantation
Julio	Mancera	julio.mancera@cloverbiosoft.com	Spain	Clover Biosoft	Antimicrobial resistance (AMR) accelerator programme	Wide experience in MS MALDI-TOF and bioinformatics
Elena	Merlo	m.e.merlo@umcg.nl	Netherlands	BiomarkerBay BV	Microenvironment imposed signatures in tissue and liquid biopsies in immune mediated disease	Expertise in bioanalysis, clinical validation, biobanking & sample collections, contacts with clinicians and academicresearchers
Astrid	Mork-Jansson	astrid.mork-jansson@uis.no	Norway	University of Stavanger		Biochemistry, molecular biology, blood brain barrier, epilepsy, exosomes in therapeutics
Alex	Neagu	alex@ttopstart.com	Netherlands	ttopstart	Blockchain enabled healthcare	
Catarina	Neves	catarinamneves@med.up.pt	Portugal	CINTESIS-FMUP	all	
Olga	Pervushina	pervushina_olga@yahoo.com	Germany	Medical Grants Pervushina&Partners	15	Monitoring of funding opportunities
Alexander	Puschilov	alexander.puschilov@viomedo.com	Germany	Viomedo	Integrated Research Platforms enabling Patient-Centric Drug Development	We operate the largest online platform that connects patients with clinical trials, working together with patient organizations.
Vaclovas	Radvilas	vaclovas.radvilas@zeclinics.com	Spain	ZeClinics SL	Translational safety technologies for human immuno-biology & Translational platforms for synaptopathy drug discovery	Generation of disease models (using zebrafish) to address the efficacy and safety of novel drugs immuno-biology and synaptopathy

IMI2 - Calls 15-16: Opportunities for SMEs

Jul 23, 2018

First Name	Last Name	Email	Country	Organisation	Which IMI2 - Call 15 & 16 topic(s) are you most interested in?	Briefly, what would you bring to the project in terms of expertise, resources, activities?
Angel Manuel	Rafael	arafael@idimas.es	Spain	IDimas Gestión	Blockchain enabled healthcare	Project management, consortium composed of public university and SME and big companies related to the topic
Andrea	Roig	aroig@zabala.es	Spain	Zabala Innovation Consulting		
Maria Grazia	Santagati	mariagrazia.santagati@tin.it	Italy	self employed		
Sibyl	Scharrer	s.scharrer@ifbhh.de	Germany	IFB Hamburg		
Sibyl	Scharret	sibylscharrer@web.de	Germany	lfb	A	
Beate	Schott	b.schott@web.de	Germany	Digital Consultancy and Project management	Call 15, Topic 2 - Blockchain	Expertise of many years working in pharmaceutical industry als internal digital consultant and project manager
Sorin	Stircu	sorin.stircu@ehealthline.com	United States	E*HealthLine	All	
Tom	Vercruysse	tom.vercruysse@kuleuven.be	Belgium	KU Leuven		
Marcus	Yeo	marcus@definigen.com	United Kingdom	Definigen Ltd.	Integrated Research Platforms enabling Patient-Centric Drug Development	CRIPSR gene-engineered induced pluripotent stem cell derived liver NASH cell models in GMP-compatible conditions
Marek	Zawada	marek.zawada@iqpharma.pl	Poland	IQ Pharma S.A.	Digital endpoints in neurodegenerative and immunemediated diseases	Clinical trials/R&D projects/Big Data/ICT solution for monitoring Parkinson's disease using wearable sensors and mobile devices
Jan	Zuidema	j.zuidema@vivomicx.eu	Netherlands	Vivomicx	Microenvironment imposed signatures in tissue and liquid biopsies in immune mediated disease	analysis of microenvironment with Laser Microdissection